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In a recent research article in BMC Medicine, Créquit and colleagues demonstrate how published systematic reviews
in lung cancer provide a fragmented, out-of-date picture of the evidence for all treatments. The results and conclusions
drawn from this study, based on cumulative network meta-analyses (NMA) of evidence from randomized clinical trials
over time, are quite compelling. The inherent waste of research resulting from incomplete evidence synthesis has
wide-reaching implications for a range of target groups including developers of systematic reviews and guidelines and
their end-users, health care professionals and patients at the point of care. Building on emerging concepts for living
systematic reviews and NMA, the authors propose "living cumulative NMA" as a potential solution and paradigmatic
shift. Here we describe how recent innovations within authoring, dissemination, and updating of systematic reviews
and trustworthy guidelines may greatly facilitate the production of living NMA. Some additional challenges need to be
solved for NMA in general, and for living cumulative NMA in particular, before a paradigmatic shift for systematic
reviews can become reality.
Please see related research article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0555-0
Keywords: Systematic reviews, Network meta-analysis, Evidence-based medicine, Knowledge translation,
Clinical practice guidelines, GRADEBackground
Health care professionals and other decision makers
responsible for providing patients with safe and high
quality care need access to the best current research
evidence about diagnosis, treatment and prognosis [1].
High quality systematic reviews synthesize the best avail-
able evidence regarding an intervention’s benefits and
harms to answer a clinical question. Clinical practice
guidelines combine this evidence with other relevant
considerations such as patients’ values and preferences
[2]. Together, reviews and guidelines constitute key tools
to provide the best current evidence and optimal recom-
mendations for choosing among alternative diagnostic
and treatment strategies [3].* Correspondence: per.vandvik@gmail.com
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in standards, methods, and systems for conducting and
reporting systematic reviews and trustworthy guidelines
[4–7]. These advances include systematic reviews that use
network meta-analyses (NMA), the statistical technique
that allows comparing multiple treatments at a time [8, 9],
the methods of which are rapidly evolving [10].
In a study recently published in BMC Medicine, Créquit
and colleagues illustrate how published systematic reviews
in lung cancer provide a fragmented, out-of-date picture
of the evidence for all treatments [11]. The evidence
covered by existing systematic reviews for second-line
treatments for advanced non-small cell lung cancer was
incomplete, with 40 % or more of treatments, treatment
comparisons, and trials missing. The incomplete evidence
was detected through the construction of cumulative
networks of evidence from randomized clinical trials over
time and an evaluation of the proportion of trials, patients,
treatments, and treatment comparisons not covered by
systematic reviews on a yearly basis from 2009 onwards.e is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ation of the scope of the systematic reviews (limited
scope may have been a legitimate reason to not include
all available trials), and failure to address the possibility
that it would have been inappropriate to pool together
the results of all the randomized trials detected. Although
these limitations may have resulted in an exaggeration of
the magnitude of the problem, the results and conclusions
are nevertheless compelling. As stated by the authors
"available pairwise treatment comparisons do not allow
for meeting clinicians’ and patients’ needs in decision
making. Nor do they meet the needs of other target
audiences such as developers of clinical practice guide-
lines, decision aids, funders and decision-makers in
health care systems" [11].
Living cumulative NMA
Building on emerging concepts for living systematic re-
views and network meta-analysis, the authors conclude
that this waste of research might be reduced by "living
cumulative NMA" (living NMA hereafter). With this
approach, the focus would be on developing NMAs that
include all available treatments (as opposed to a series of
head-to-head comparisons), which are updated as soon
as new trials become available. The authors propose
methodological steps for living NMA and present a
series of challenges and potential solutions for each step
from creation to dissemination and updating. Their pro-
posed solution represents an innovative input to existing
challenges for systematic reviews and also relates to
international calls for increased value and reduced waste
in research, here within the context of evidence synthesis
of available trials [12].
Although producing living NMAs is challenging, recent
developments could greatly facilitate their production.
Improved methods, strategies, and tools for more efficient
authoring, dissemination, and updating of systematic re-
views and trustworthy guidelines are emerging [13–15].
Tools, such as the Epistemonikos database, allow efficient
and intuitive searching for systematic reviews and indi-
vidual studies [16]. The use of GRADE combined with
innovative health information technology (e.g., MAGICapp)
facilitates dynamically updated digitally structured evidence
summaries, guidelines, and decision aids that clinicians and
patients can access on all devices in user-friendly formats
[3, 14, 15, 17, 18]. Presentations on these devices include
desirable and undesirable consequences of treatment alter-
natives customized for both shared decision-making and
integration in electronic medical records linked to patient
specific data [14, 19].
These innovations, however, have not fully addressed
all the challenges related to NMA in general, and to living
cumulative NMA in particular. We will now comment on
some additional challenges and suggest potential solutionsfrom the perspective of developers of systematic reviews
and guidelines and their end-users, health care profes-
sionals and patients at the point of care.
Rating quality of evidence in NMA
Systematic reviews need to perform an appropriate assess-
ment of the quality of the body of evidence (synonyms:
certainty or confidence in the evidence) for patient-
important outcomes [5, 7]. State of the art reviews now
provide evidence summaries using GRADE Summary
of Findings (SoF) tables that provide quality of evidence
ratings to inform clinicians, patients, guideline developers,
and policy decision-makers [20].
Créquit and co-authors point out that guideline de-
velopers and other decision-makers may further benefit
from NMAs if they rate the quality of the body of
evidence supporting treatment effect estimates for all
patient-important outcomes. Rating quality of evidence
in NMA presents additional challenges and represents
a methodological frontier. Authors have already pre-
sented two systems based on GRADE principles for
making quality of evidence ratings in NMAs [21, 22].
Much work remains in the testing, application, and refine-
ment of these methods, currently being undertaken by
(among others) the GRADE NMA project group [23].
Patient-important outcomes in NMA
Systematic reviews and trustworthy guidelines need to
provide evidence for all outcomes to allow an assessment
of the balance between the desirable and undesirable con-
sequences of a course of action [4, 24]. The Créquit study
focused on the availability of treatment comparisons for
lung cancer rather than on the extent to which authors
synthesized evidence across all patient-important out-
comes. As acknowledged by the authors, the identification
and reporting of all outcomes that are important to pa-
tients for decision-making in living NMA represents a
particular challenge, including differential reporting across
outcomes resulting in variation in the geometry of the
network of trials. Further methodological work in NMA
will be required to address these issues.
Dissemination of results from NMA to the point of care
Health care professionals and patients will, as outlined
above, increasingly be able to access the best current evi-
dence from systematic reviews and recommendations in
guidelines at the point of care in new and user-friendly
formats [3, 14, 19]. Interactive Summary of Findings
(iSoF) tables represent one such innovation with new and
improved presentation formats of evidence summaries
linked to systematic reviews and guidelines. iSoF tables
allow end-users to balance benefits and harms in absolute
numbers, also taking into account the quality of the
evidence [25].
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parisons, and so do not address the multiple comparisons
of NMA. How to best present multiple comparisons for
all patient-important outcomes to end-users remains un-
investigated. Members of the GRADE NMA project group
are exploring both how to optimally present the results
from NMA in SoF tables and how to translate relative
estimates of effects (the output obtained from NMA) into
absolute estimates of effect that facilitate the decision-
making process [23].
Conclusions
The traditional methods of conducting systematic reviews
are associated with a risk of presenting an incomplete pic-
ture of the relevant evidence addressing a clinical ques-
tion. Living NMA represents a promising approach to
providing a broad, complete, and updated presentation of
the evidence regarding all the available management
options. This might well represent a paradigmatic shift
for systematic reviews. However, as is the case for any
new technology, living NMA will require overcoming a
number of challenges. Investigators are currently ad-
dressing these challenges which suggest that living
NMA as a new tool for addressing clinical questions
may, in the near future, become available.
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